more

The Cooper Companies (COO)

(Delayed Data from NSDQ)

$92.69 USD

+0.08 (0.09%)

Updated Jul 30, 2024 04:00 PM ET

After-Market: $93.10 +0.41 (0.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

Bottom 19% (203 out of 251)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.

Catalent (CTLT) Declines on Profit Warnings and CFO Exit

by Zacks Equity Research Published on April 18,2023

Catalent (CTLT) issues a profit warning for third-quarter fiscal 2023 amid supply chain disruptions and operational challenges. It also announces the departure of its CFO.

medical

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research Published on April 17,2023

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

medical

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio

by Zacks Equity Research Published on April 13,2023

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

medical

Here's Why You Should Retain Catalent (CTLT) Stock for Now

by Zacks Equity Research Published on April 12,2023

Catalent's (CTLT) product and service launches, and a slew of strategic deals raise optimism about the stock.

medical

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research Published on April 06,2023

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on the company.

medical

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research Published on April 06,2023

Investors continue to feel optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.

medical

Here's Why You Should Retain Inari Medical (NARI) Stock Now

by Zacks Equity Research Published on April 05,2023

Inari Medical (NARI) continues to benefit from its commitment to understand the venous system. However, its dependency on the adoption of products is concerning.

medical

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research Published on April 04,2023

Investors continue to be optimistic about CONMED (CNMD), owing to its broad product spectrum.

medical

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

by Zacks Equity Research Published on April 03,2023

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

medical

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research Published on March 30,2023

XRAY vs. COO: Which Stock Is the Better Value Option?

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research Published on March 29,2023

The Cooper Companies (COO) continues to benefit from strength in its business segments. Its acquisitions are likely to drive the top line further.

medical

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Stock Now

by Zacks Equity Research Published on March 27,2023

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, macroeconomic factors like weakened global demand, rising costs and forex woes persist.

medical

Dexcom (DXCM) Launches G6 Glucose Monitoring System in Canada

by Zacks Equity Research Published on March 24,2023

Dexcom (DXCM) announces the availability of standard of care in diabetes management - G6 CGM system - for type 1 and 2 patients with basal and bolus insulin or using an insulin pump in Canada.

medical

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

by Zacks Equity Research Published on March 24,2023

PerkinElmer (PKI) continues to gain from a solid product portfolio despite forex woes.

medical

Reasons to Retain West Pharmaceutical (WST) in Your Portfolio

by Zacks Equity Research Published on March 23,2023

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.

medical

Here's Why You Should Retain Patterson Companies (PDCO) Stock

by Zacks Equity Research Published on March 23,2023

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

medical

Catalent (CTLT) Inks Deal for New & Effective Drug Delivery

by Zacks Equity Research Published on March 20,2023

Catalent (CTLT) will use Bhami Research Laboratory's technology to evaluate and develop drug-delivery system for high-concentration therapies, thereby increasing effectiveness.

medical

Is Clene (CLNN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research Published on March 16,2023

Here is how Clene Inc. (CLNN) and The Cooper Companies (COO) have performed compared to their sector so far this year.

Reasons to Retain Cardinal Health (CAH) in Your Portfolio

by Zacks Equity Research Published on March 16,2023

Cardinal Health (CAH) continues to gain traction from solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.

medical

earnings